Pricing
  1. JP-listed companies
  3. Financials
  4. Total non-current assets

【JP:4597】

Market cap
¥7B
P/E ratio
Develops and commercializes innovative cancer medicines across Asian markets including Japan, China, and South Korea, focusing on treatments and supportive care.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal non-current assets (Million JPY)YoY (%)
Dec 31, 2025254+164.58%
Dec 31, 202496-92.33%
Dec 31, 20231,252-26.27%
Dec 31, 20221,698-24.50%
Dec 31, 20212,249-10.26%
Dec 31, 20202,506-31.23%
Dec 31, 20193,644+3337.74%
Dec 31, 2018106+47.36%
Dec 31, 201772+101.15%
Dec 31, 201636-0.80%
Dec 31, 201536

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)